Sp1043
INTRODUCTION
Date
May 9, 2023
Explore related products in the following collection:
Society: AGA
AGA guidelines are among the most rigorously evidence-based and trusted guidelines in the field of GI and hepatology. This session will give DDW attendees the rare opportunity to hear about newly published and upcoming AGA guidelines from the authors of the guideline themselves, including a Question and Answer portion. It also provides an additional public forum to have the guidelines heard and discussed, in addition to our 30-day public comment period, contributing to an open and transparent process of guideline development.
AGA guidelines are among the most rigorously evidence-based and trusted guidelines in the field of GI and hepatology. This session will give DDW attendees the rare opportunity to hear about newly published and upcoming AGA guidelines from the authors of the guideline themselves, including a Question and Answer portion. It also provides an additional public forum to have the guidelines heard and discussed, in addition to our 30-day public comment period, contributing to an open and transparent process of guideline development.
Presenter
University of California San Diego
Tracks
Related Products
ESTIMATED BURDEN OF SCREENING FOR BARRETT’S ESOPHAGUS IN THE UNITED STATES
Barrett’s esophagus (BE), a pre-malignant precursor of esophageal adenocarcinoma (EAC), when recognized early through screening, could potentially allow for endoscopic surveillance or endoscopic eradication therapy…
REAL WORLD IMPLEMENTATION OF TREAT-TO-TARGET IN PATIENTS WITH IBD IN A LEARNING HEALTH SYSTEM: AN IBD QORUS COLLABORATIVE STUDY
BACKGROUND AND AIMS: A treat-to-target (TTT) strategy of striving for symptomatic and endoscopic remission is recommended for the management of inflammatory bowel diseases (IBD). Yet, real-world uptake of TTT strategies has been modest…
MONITORING OF CALPROTECTIN IN INFLAMMATORY BOWEL DISEASE USING A SWEAT BASED WEARABLE DEVICE
Switching from originator to biosimilar infliximab (IFX) is effective and safe. However, data on multiple switching are scarce. The Edinburgh IBD unit has undertaken three switch programmes: (1) Remicade to CT-P13 (2016), (2) CT-P13 to SB2 (2020), and (3) SB2 to CT-P13 (2021)…
INTRODUCTION
SOCIETY: AGA
